// App-Quantinova.ai

OP0086 (2018) : Long-term efficacy and safety of adalimumab by immunosuppressant use in patients with non-infectious uveitis in the visual iii trial

Researchers

Presenter

  • Y. Guex-Crosier

Principal Investigators

  • C.S. Foster

  • K. Nakai

  • H. Goto

  • K. Douglas

  • S. Pathai

  • M. Kron

  • A.P. Song

  • J. Van Calster

  • A. Adán

Medical Centers

  • Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland

  • Massachusetts Eye Research and Surgery Institution (MERSI), Ocular Immunology & Uveitis Foundation (OIUF), Waltham, Maine, United States

  • Harvard Medical School, Boston, MA

  • Yodogawa Christian Hospital, Osaka, Japan

  • Tokyo Medical and Dental University, Tokyo, Japan

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Inc., Maidenhead, UK

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Hospital Clinic Barcelona, Barcelona, Spain

Locations

  • Switzerland

  • United States

  • Japan

  • United Kingdom

  • Germany

  • Belgium

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

Disease

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Oraprine

  • Cyclosporine eent

  • Methotrexate

  • Adalimumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • AbbVie Inc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved